基底细胞癌是否起源于前驱病变?
基底细胞癌几乎均由Hedgehog信号通路上游的PTCH1失活或SMO激活突变驱动,但临床上尚未发现明确的前驱病变。近期人和小鼠肿瘤的基因组分析提示,BCC形成除PTCH1或SMO突变外还需额外遗传改变,支持部分BCC遵循多步突变累积的渐进模型。基于Gorlin综合征患者的研究,作者推测至少部分BCC起源于亚临床基底样毛囊错构瘤或类似前驱病变。
要点
- 上游HH信号激活是BCC发生的必要条件但非充分条件。
- 部分BCC可能遵循多步突变累积的渐进性肿瘤进展模型。
- Gorlin综合征的亚临床基底样毛囊错构瘤可能是部分BCC的前驱病变。
核心结论
- 激活上游HH信号是BCC形成的必要条件但非充分条件。
- 部分BCC可能遵循多步突变累积的渐进模型,起源于亚临床前驱病变。
研究设计与样本
- 基于人和小鼠肿瘤的近期基因组分析及Gorlin综合征患者研究的推测性综述。
主要发现
- BCC几乎均由PTCH1功能缺失突变或SMO功能获得突变驱动。
- BCC形成除PTCH1或SMO突变外还需额外遗传改变。
- 至少部分BCC可能起源于亚临床基底样毛囊错构瘤或类似前驱病变。
临床怎么用
- 需重新审视BCC小鼠模型结果的解读。
- 对BCC基本认识和治疗策略具有潜在指导意义。
局限性
- 前驱病变的推测基于Gorlin综合征患者研究,尚未在一般人群中证实。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Basal cell carcinoma (BCC) is driven in nearly all cases by mutations that constitutively activate upstream Hedgehog (HH) signaling, either through loss-of-function mutations in PTCH1 or gain-of-function mutations in SMO. Unlike other skin cancers such as squamous cell carcinoma, a clinically apparent precursor lesion for BCC has not been identified. Recent genomic analyses of both human and mouse tumors suggest that BCC formation requires not only PTCH1 or SMO mutations but also additional genetic changes. These findings imply that some BCCs may follow a stepwise tumor progression model, whereby the accumulation of multiple mutational "hits" is needed to convert an indolent precursor lesion into malignant disease. On the basis of studies in patients with Gorlin syndrome who harbor germline PTCH1 mutations and are genetically predisposed to forming BCC, we speculate that at least a subset of BCCs arises from a subclinical basaloid follicular hamartoma or similar precursor lesion. Altogether, convergent evidence suggests that activating upstream HH signaling is necessary but not sufficient for BCC formation. This evolving view of BCC has important implications for our basic understanding of these tumors, for our interpretation of findings from BCC mouse models, and for guiding treatment.
引用
- Wong SY, Harms PW, Dlugosz AA, et al. Does Basal Cell Carcinoma Arise from a Precursor Lesion? J Invest Dermatol. 2025. PMID: 41240053. doi:10.1016/j.jid.2025.09.381
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。